Table 1.

Expression levels of six potential biomarkers in patients with high-risk prostate cancer who underwent radical prostatectomy with and without neoadjuvant treatment

				NNA	NHT	CHT	p-value	p value (NNA vs. CHT)	p value (NHT vs. CHT)
AR	Epithelial cells	Nuclear	Area	3.01 ± 0.10	2.06 ± 0.13	2.07 ± 0.0.06	< 0.001	< 0.001	0.984
			Intensity	2.27 ± 0.08	1.94 ± 0.12	1.79 ± 0.05	< 0.001	< 0.001	0.208
			Immunoreactivity score	7.20 ± 0.39	4.50 ± 0.40	4.16 ± 0.18	< 0.001	< 0.001	0.441
		Cytoplasmic	Potitive/Negative (% of positive)	60/22 (73.2%)	48/16 (75.0%)	82/162 (33.6%)	< 0.001	< 0.001	< 0.001
	Stromal cells		Area	1.21 ± 0.65	1.72 ± 0.81	1.55 ± 0.64	< 0.001	< 0.001	0.077
			Intensity	1.08 ± 0.06	1.50 ± 0.08	1.33 ± 0.04	< 0.001	< 0.001	0.034
			Immunoreactivity score	1.54 ± 0.14	2.94 ± 0.24	2.26 ± 0.10	< 0.001	< 0.001	0.010
GR	Epithelial cells	Nuclear	Area	1.80 ± 0.10	1.69 ± 0.13	2.36 ± 0.05	< 0.001	< 0.001	< 0.001
			Intensity	1.55 ± 0.10	1.66 ± 0.12	1.88 ± 0.06	0.009	0.004	0.076
			Immunoreactivity score	3.35 ± 0.29	3.38 ± 0.37	4.83 ± 0.20	< 0.001	< 0.001	0.001
		Cytoplasmic	Potitive/Negative (% of positive)	0/80 (0%)	0/64 (0%)	38/196 (16.2%)	< 0.001	< 0.001	0.001
	Stromal cells		Area	1.92 ± 0.07	1.78 ± 0.06	1.77 ± 0.05	0.180	0.055	0.875
			Intensity	2.82 ± 0.02	2.88 ± 0.04	2.92 ± 0.03	0.133	0.049	0.396
			Immunoreactivity score	5.41 ± 0.20	5.13 ± 0.19	5.23 ± 0.14	0.663	0.452	0.672
ERα	Stromal cells	Nuclear	Area	0.73 ± 0.08	1.13 ± 0.11	1.24 ± 007	< 0.001	< 0.001	0.392
			Intensity	0.65 ± 0.07	1.19 ± 0.12	1.32 ± 0.07	< 0.001	< 0.001	0.391
			Immunoreactivity score	0.85 ± 0.11	1.97 ± 0.25	2.51 ± 0.17	< 0.001	< 0.001	0.074
PR	Epithelial cells	Cytoplasmic	Area	0.82 ± 0.08	0.28 ± 0.07	0.30 ± 0.04	< 0.001	< 0.001	0.808
			Intensity	1.54 ± 0.14	0.38 ± 0.09	0.52 ± 0.06	< 0.001	< 0.001	0.197
			Immunoreactivity score	1.82 ± 0.20	0.50 ± 0.14	0.63 ± 0.08	< 0.001	< 0.001	0.455
	Stromal cells	Nuclear	Area	1.13 ± 0.06	1.56 ± 0.09	2.30 ± 0.04	< 0.001	< 0.001	< 0.001
			Intensity	2.24 ± 0.11	2.47 ± 0.09	2.94 ± 0.02	< 0.001	< 0.001	< 0.001
			Immunoreactivity score	2.85 ± 0.19	3.75 ± 0.24	6.76 ± 0.14	< 0.001	< 0.001	< 0.001
MOB4A	Epithelial cells	Cytoplasmic	Area	2.21 ± 0.13	2.06 ± 0.15	2.63 ± 0.05	< 0.001	0.002	0.001
			Intensity	1.09 ± 0.08	1.20 ± 0.11	1.49 ± 0.04	< 0.001	< 0.001	0.014
			Immunoreactivity score	2.93 ± 0.24	3.20 ± 0.31	4.09 ± 0.13	< 0.001	< 0.001	0.004
YAP1	Epithelial cells	Nuclear	Area	1.54 ± 0.09	1.27 ± 0.15	1.76 ± 0.06	< 0.001	0.048	0.002
			Intensity	1.68 ± 0.11	1.27 ± 0.15	1.78 ± 0.05	< 0.001	0.377	0.002
			Immunoreactivity score	3.03 ± 0.24	2.83 ± 0.42	3.55 ± 0.17	0.086	0.104	0.113
		Cytoplasmic	Area	1.95 ± 0.12	1.73 ± 0.14	2.42 ± 0.06	< 0.001	< 0.001	< 0.001
			Intensity	1.14 ± 0.05	1.23 ± 0.08	1.73 ± 0.11	< 0.001	< 0.001	< 0.001
			Immunoreactivity score	2.57 ± 0.26	2.90 ± 0.32	4.71 ± 0.20	< 0.001	< 0.001	< 0.001

NNA no neoadjuvant threatment, NHT neoadjuvant hormonal therapy, CHT neoadjuvant chemohormonal therapy, AR androgen receptor, GR glucocorticoid receptor, ER estrogen receptor, PR progesterone receptor